Results 71 to 80 of about 5,558,618 (260)

An epithelial GPR35 isoform supports tumor‐associated transcriptional and metabolic phenotypes

open access: yesFEBS Letters, EarlyView.
GPR35 generates two functionally distinct isoforms with previously unresolved roles. GPR35‐short mediates immune‐cell chemotaxis, while GPR35‐long is enriched in colorectal cancer epithelium, where it supports increased metabolism, proliferation, and tumor‐associated transcriptional programs.
Jørgen D. Rønneberg   +14 more
wiley   +1 more source

Measuring drug similarity using drug–drug interactions

open access: yesQuantitative Biology
Combination therapy is a promising approach to address the challenge of antimicrobial resistance, and computational models have been proposed for predicting drug–drug interactions.
Ji Lv   +4 more
doaj   +1 more source

Structure‐forward targeting of claudins with synthetic binders

open access: yesFEBS Letters, EarlyView.
Claudins form the paracellular barriers between epithelial and endothelial tissues at tight junctions and are targets for molecular binders with the goal of modulating barrier permeability. Claudin‐binding molecules are relevant in drug delivery or in altering claudin interactions with disease‐causing proteins.
Alex J. Vecchio
wiley   +1 more source

Conformational analysis of fenoterol stereoisomers

open access: yesCurrent Issues in Pharmacy and Medical Sciences
Fenoterol is a relatively long-acting selective agonist of β2 adrenergic receptor (β2-AR) used in the treatment of asthma. Its molecule contains two stereogenic centers, thus, the compound exists as four stereoisomers.
Anita Płazińska   +2 more
doaj  

Discerning protein pools by selective staining with self‐labeling tags

open access: yesFEBS Letters, EarlyView.
Cell surface proteins have an intra‐ and extracellular pool. Combining genetic fusion to self‐labeling tags that can be addressed with small molecule fluorophores allows separating these pools. We highlight recent developments and techniques for state‐of‐the‐art interrogation of cell surface proteins in the complex tissue setting.
Kati Fischermanns, Johannes Broichhagen
wiley   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

open access: yesFEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang   +2 more
wiley   +1 more source

Drug-nucleic acid interactions /

open access: yes, 2001
This volume consolidates the key methods for studying ligand-nucleic acid interactions into a convenient source. Techniques that are examined range from biophysical and chemical approaches to methods rooted in molecular and cell biology.Includes ...
Chaires, Jonathan B.,editor.   +1 more
core  

Potential Drug-drug Interactions in Intensive Care Units in Turkey: A Point Prevalence Study

open access: yes, 2023
Objective:Drug-drug interaction (DDI) is related with complications and diminished efficacy of medications throughout the treatment process. Intensive care units (ICU) involve patients who are at elevated risk of potential drug-drug interactions (pDDI ...
Melike Şeyda Dağdelen   +3 more
core   +1 more source

Multimodal Nanobiophysical Profiling of Melanoma-Derived Small Extracellular Vesicles Reveals Glycan Signatures Associated with Tumor Progression

open access: yesNanotechnology, Science and Applications
Swamy Kasarla,1 Karolina Staniak,1,2 Magdalena Surman,3 Krystian Zajączkowski,1 Alicja Targońska,2 Grażyna Mosieniak,2 Konstancja Bobecka-Wesołowska,4 Josef Uskoba,5 Małgorzata Przybyło,3 ...
Kasarla S   +9 more
doaj  

Drug interactions in epilepsy

open access: yesArquivos de Neuro-Psiquiatria, 1980
Interactions with antiepileptic drugs are common and may have important clinical consequences. The physician should always consider carefully the need for and the implications of adding a new drug to any therapeutic regime and should be prepared to think
Emilio Perucca
doaj   +1 more source

Home - About - Disclaimer - Privacy